

FILE 'HOME' ENTERED AT 15:52:37 ON 13 JUL 2006

=> b caplus biosis scisearch medline
COST IN U.S. DOLLARS

SINCE FILE ENTRY	TOTAL SESSION
1.47	1.47

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 15:56:55 ON 13 JUL 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 15:56:55 ON 13 JUL 2006
Copyright (c) 2006 The Thomson Corporation

FILE 'SCISEARCH' ENTERED AT 15:56:55 ON 13 JUL 2006
Copyright (c) 2006 The Thomson Corporation

FILE 'MEDLINE' ENTERED AT 15:56:55 ON 13 JUL 2006

=> s treatment and drug and conversion
L1 12882 TREATMENT AND DRUG AND CONVERSION

=> s l1 and treatment(P) conversion
L2 11147 L1 AND TREATMENT(P) CONVERSION

=> s l2 and octreotide and pegvisomant
L3 3 L2 AND OCTREOTIDE AND PEGVISOMANT

=> dup remo l3
PROCESSING COMPLETED FOR L3
L4 2 DUP REMO L3 (1 DUPLICATE REMOVED)

=> d l4 1-2 bib abs

L4 ANSWER 1 OF 2 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
DUPLICATE 1
AN 2005:468947 BIOSIS
DN PREV200510254072
TI Glucose homeostasis and safety in patients with acromegaly converted from
long-acting octreotide to pegvisomant.
AU Barkan, Ariel L. [Reprint Author]; Burman, Pia; Clemmons, David R.; Drake,
William M.; Gagel, Robert F.; Harris, Philip E.; Trainer, Peter J.; van
der Lely, Aart Jan; Vance, Mary Lee
CS Univ Michigan, Med Ctr, Dept Internal Med, 3920 Taubman Ctr, Ann Arbor, MI
48109 USA
abarkan@med.umich.edu
SO Journal of Clinical Endocrinology & Metabolism, (OCT 2005) Vol. 90, No.
10, pp. 5684-5691.
CODEN: JCEMAZ. ISSN: 0021-972X.
DT Article
LA English
ED Entered STN: 9 Nov 2005
Last Updated on STN: 9 Nov 2005
AB Context: In clinical practice, patients with acromegaly may be switched
from therapy with long-acting somatostatin analogs to pegvisomant
. The effect of changing therapies on glucose homeostasis and safety has
not been reported.Objectives: The objectives of this study were to monitor
changes in IGF-I levels, glycemic control, and safety, particularly liver
function and tumor size.Design: This was a multicenter, open-label, 32-wk
trial study.Setting: The study was performed at outpatient
clinics.Patients: Fifty-three patients with acromegaly previously treated
with octreotide long-acting release (LAR) participated in this

study. Intervention: Pegvisomant (10 mg/d) was initiated 4 wk after the last dose of octreotide LAR and was adjusted based on serum IGF-I concentrations at wk 12, 20, and 28. Main Outcome Measures: The main outcome measures were changes in IGF-I, glycosylated hemoglobin A(1c) (HbA(1c)), fasting plasma glucose, and safety during the first 12 wk after conversion. Results: At the end of pegvisomant treatment, IGF-I was normalized in 78% of patients. At wk 32, median fasting glucose concentration and HbA(1c) were reduced (-1.4 mmol/liter and -0.4%, respectively; both $P \leq 0.0001$) in the study population. Improvements in glycemic control occurred in patients with normal IGF-I concentrations at wk 4 [$n = 15$; fasting glucose, -1.7 mmol/liter ($P \leq 0.0001$); HbA(1c) -0.2% ($P = 0.03$)]. Decreases in fasting glucose and HbA(1c) levels were observed in patients with and without diabetes. HbA(1c) was reduced by more than 1.0% in patients with diabetes. Median pituitary tumor volume did not change, although tumor volume increased in two patients with macroadenomas. Conclusions: Conversion from octreotide LAR to pegvisomant was safe and well tolerated. Improved glycemic control indicates that pegvisomant should be considered in patients with acromegaly and diabetes.

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2006 ACS on STM

AN 2004:927079 CAPLUS

DN 141:360723

TI Growth hormone receptor antagonist-COX-2 inhibitor combination with antihypertension agents for use in treatment of patients with acromegaly

IN Fryklund, Linda; Harris, Philip

PA Pharmacia & Upjohn Company, USA

SO PCT Int. Appl., 54 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004093913	A1	20041104	WO 2004-GB1771	20040426
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRAI GB 2003-9328 A 20030424

AB The invention provides a method for the treatment of hypertension in a patient characterized by using a growth hormone receptor antagonist in combination with an antihypertension agent.

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>

=> d his

(FILE 'HOME' ENTERED AT 15:52:37 ON 13 JUL 2006)

FILE 'CAPLUS, BIOSIS, SCISEARCH, MEDLINE' ENTERED AT 15:56:55 ON 13 JUL 2006

L1 12882 S TREATMENT AND DRUG AND CONVERSION

L2 11147 S L1 AND TREATMENT(P) CONVERSION
L3 3 S L2 AND OCTREOTIDE AND PEGVISOMANT
L4 2 DUP REMO L3 (1 DUPLICATE REMOVED)

WEST Search History

DATE: Thursday, July 13, 2006

Hide?	Set Name	Query	Hit Count
		<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; PLUR=YES; OP=OR</i>	
<input type="checkbox"/>	L4	treatment same drug same conversion same overlap	3
<input type="checkbox"/>	L3	octreotide and L2	14
<input type="checkbox"/>	L2	pegvisomant and acromeg\$	26
<input type="checkbox"/>	L1	pegvisomant.clm.	9

END OF SEARCH HISTORY